Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment